<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724540</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 01215</org_study_id>
    <nct_id>NCT02724540</nct_id>
  </id_info>
  <brief_title>Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver</brief_title>
  <official_title>Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this trial is to estimate the duration of hepatic progression-free
      survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial
      Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary
      hypothesis is that chemoembolization will be nearly twice as durable as bland embolization;
      thatis, the hazard ratio for HPFS will be 1.76 or better.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal MRI/Triple Phase CT</measure>
    <time_frame>2 years</time_frame>
    <description>Hepatic progression-free interval (H-PFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Symptom-relief interval and toxicity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Neuroendocrine Tumor, Malignant</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Arm 1 - BE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobar or segmental bland embolization (BE) with microspheres (50-500 microns) to 2-5 heartbeat stasis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobar or segmental lipiodol conventional transarterial chemoembolization (TACE). Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - DEB - CLOSED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bland Embolization</intervention_name>
    <description>Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis</description>
    <arm_group_label>Arm 1 - BE</arm_group_label>
    <other_name>BE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Transarterial chemoembolization</intervention_name>
    <description>Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.</description>
    <arm_group_label>Arm 2 - TACE</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Drug Eluting Beads Embolization</intervention_name>
    <description>CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.</description>
    <arm_group_label>Arm 3 - DEB - CLOSED</arm_group_label>
    <other_name>DEB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants 18 years and older;

          -  Biopsy-proven neuroendocrine tumor.

          -  Measurable metastasis to liver with at least one dimension ≥ 1.0 cm.

          -  Tumor burden dominant in the liver AND liver tumor burden less than or equal to 70% of
             the total liver volume by visual estimate.

          -  Not a candidate for surgical resection based on unresectability, anatomy, anesthesia
             risk, patient preference.

          -  Symptoms uncontrolled by somatostatin analogues OR morphologically progressive tumor
             by RECIST 1.1 criteria in the liver OR baseline tumor burden &gt;25% of the liver volume.

          -  There must be no plans for the patient to receive other concomitant therapy while on
             this protocol treatment (other than somatostatin analogs or bone-strengthening
             agents).

          -  Performance status 0-2 on Zubrod/ECOG Performance Scale;

          -  Serum creatinine &lt; 2.0 mg/dL;

          -  Serum Bilirubin ≤ 2.0 mg/dL

          -  Serum albumin ≥ 3.0 g/dL

          -  Platelet count &gt; 50 thousands/uL (corrected if needed)

          -  INR ≤ 1.5 (corrected if needed)

          -  All patients must be informed of the investigational nature of this study and must
             sign a study specific informed consent in accordance with institutional and federal
             guidelines prior to study entry.

        Exclusion Criteria:

          -  Pregnant or lactating women may not participate due to the embryotoxic effects of
             protocol treatment. Women/men of reproductive potential may not participate unless
             they have agreed to use an effective contraceptive method.

          -  Prior hepatic arterial therapy or hepatic radiation therapy. Prior surgical resection
             or ablation of liver metastases is acceptable. Patients must be at least one month
             beyond prior chemotherapy, PRRT, ablation or surgery, and have recovered from all
             therapy-associated toxicities.

          -  Active infection (Symptomatic bacterial and fungal infection - newly diagnosed and/or
             requiring treatment);

          -  Choledochoenteric anastomosis; transpapillary biliary stent, or sphincterotomy of
             duodenal papilla

          -  Absolute contraindication to intravenous iodinated contrast (Hx of significant
             previous contrast reaction, not mitigated by appropriate pre-medication).

          -  Contraindications to arteriography and selective visceral catheterization:

               1. severe allergy or intolerance to contrast media, narcotics, sedatives, or
                  atropine.

               2. bleeding diathesis not correctable by usual forms of therapy.

               3. severe peripheral vascular disease precluding catheterization.

          -  Contraindications to hepatic artery embolization:

               1. portal vein occlusion without hepatopedal collateral flow demonstrated by
                  angiography; or portal hypertension with hepatofugal flow.

               2. hepatic encephalopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C Soulen, MD, FSIR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael C Soulen, MD, FSIR</last_name>
    <phone>855-216-0098</phone>
    <email>michael.soulen@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Feldman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicholas Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nishita Kothary, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nishita Kothary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghassan El-Haddad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ghassan El-Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Wolin</last_name>
    </contact>
    <investigator>
      <last_name>Edward Wolin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etay Ziv</last_name>
    </contact>
    <investigator>
      <last_name>Etay Ziv</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Kolbeck, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kenneth Kolbeck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael C Soulen, MD, FSIR</last_name>
      <phone>855-216-0098</phone>
      <email>michael.soulen@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael C Soulen, MD, FSIR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rony Avritscher, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rony Avritscher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah B White, MD, MS</last_name>
    </contact>
    <investigator>
      <last_name>Sarah B White, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1191 ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Monaco-Garcia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Monaco-Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Dey</last_name>
    </contact>
    <investigator>
      <last_name>Chris Dey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco DeCobelli</last_name>
    </contact>
    <investigator>
      <last_name>Francesco DeCobelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

